X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lenvatinib (308) 308
index medicus (140) 140
sorafenib (106) 106
thyroid cancer (106) 106
oncology (104) 104
humans (94) 94
tyrosine kinase inhibitor (79) 79
cancer (76) 76
carcinoma (56) 56
e7080 (53) 53
pharmacology & pharmacy (48) 48
double-blind (47) 47
female (47) 47
angiogenesis (46) 46
metastasis (43) 43
hepatocellular carcinoma (42) 42
male (41) 41
thyroid (41) 41
antineoplastic agents - therapeutic use (40) 40
patients (40) 40
phenylurea compounds - adverse effects (40) 40
thyroid neoplasms - drug therapy (40) 40
quinolines - adverse effects (39) 39
tumors (39) 39
vascular endothelial growth factor (38) 38
differentiated thyroid cancer (37) 37
middle aged (37) 37
tyrosine (37) 37
phenylurea compounds - therapeutic use (35) 35
cabozantinib (34) 34
quinolines - therapeutic use (34) 34
protein kinase inhibitors - therapeutic use (33) 33
therapy (33) 33
endocrinology & metabolism (32) 32
care and treatment (31) 31
aged (30) 30
everolimus (30) 30
targeted therapy (30) 30
antitumor activities (29) 29
cancer therapies (29) 29
medicine & public health (29) 29
tyrosine kinase inhibitors (29) 29
endothelial growth-factor (28) 28
hypertension (28) 28
treatment outcome (28) 28
drug therapy (27) 27
metastases (26) 26
analysis (25) 25
antineoplastic agents - adverse effects (25) 25
phenylurea compounds - administration & dosage (25) 25
adult (24) 24
advanced solid tumors (24) 24
liver cancer (24) 24
quinolines - administration & dosage (24) 24
regorafenib (24) 24
vandetanib (24) 24
kinases (23) 23
survival (23) 23
chemotherapy (22) 22
clinical trials (22) 22
nivolumab (22) 22
review (22) 22
anaplastic thyroid cancer (21) 21
medical prognosis (21) 21
protein kinase inhibitors - adverse effects (21) 21
research (21) 21
sunitinib (21) 21
management (20) 20
papillary (20) 20
solid tumors (20) 20
animals (19) 19
immunotherapy (19) 19
inhibitor (19) 19
neoplasms. tumors. oncology. including cancer and carcinogens (19) 19
pharmacokinetics (19) 19
protein-tyrosine kinase (19) 19
thyroid neoplasms - pathology (19) 19
trial (19) 19
aged, 80 and over (18) 18
surgery (18) 18
甲状せん (18) 18
甲状腺 (18) 18
efficacy (17) 17
iodine (17) 17
open-label (17) 17
phase-ii trial (17) 17
toxicity (17) 17
phenylurea compounds - pharmacokinetics (16) 16
prognosis (16) 16
quinolines - pharmacokinetics (16) 16
safety (16) 16
studies (16) 16
axitinib (15) 15
development and progression (15) 15
expression (15) 15
iodine radioisotopes (15) 15
レンバチニブ (15) 15
甲状腺癌 (15) 15
bevacizumab (14) 14
carcinoma, renal cell - drug therapy (14) 14
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (284) 284
Japanese (22) 22
Russian (13) 13
French (4) 4
German (2) 2
Korean (2) 2
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 08/2017, Volume 44, Issue 8, pp. 695 - 697
Journal Article
Frontiers in Oncology, ISSN 2234-943X, 03/2017, Volume 7, pp. 25 - 25
Lenvatinib has been approved by regulatory agencies in Japan, the United States, and the European Union for treatment of radioiodine-refractory differentiated... 
Clinical trial | Anaplastic thyroid cancer | Lenvatinib | Phase 2 | Tyrosine kinase inhibitor
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 05/2019, Volume 104, Issue 5, pp. 1417 - 1428
Context: BRAF(V600E) mutant thyroid cancers are often refractory to radioiodine (RAI). Objectives: To investigate the utility and molecular underpinnings of... 
CELLS | MULTICENTER | LENVATINIB | THERAPY | INHIBITION | I-124 | ENDOCRINOLOGY & METABOLISM | DEDIFFERENTIATION | PAPILLARY | RADIOACTIVE IODINE | CARCINOMA
Journal Article
Cancer, ISSN 0008-543X, 08/2015, Volume 121, Issue 16, pp. 2749 - 2756
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 03/2019, Volume 15, Issue 7, pp. 717 - 726
Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer. Patients/methods: In this Phase II study, 51 Japanese patients with... 
NEUTROPHIL | lenvatinib | LENVATINIB E7080 | METASTASES | medullary | SORAFENIB | ANTITUMOR ACTIVITIES | CANCER | radioiodine-refractory differentiated thyroid cancer | LYMPHOCYTE RATIO | thyroid carcinoma | anaplastic | ONCOLOGY | INHIBITOR | CARCINOMA | CLINICAL-OUTCOMES
Journal Article
Endocrine Journal, ISSN 0918-8959, 2017
Although advanced thyroid carcinoma patients who cannot be cured by conventional therapy have lacked effective treatment, multitargeted tyrosine kinase... 
Early tumor shrinkage | Lenvatinib | Thyroid carcinoma
Journal Article
Japanese Journal of Head and Neck Cancer, ISSN 1349-5747, 2018, Volume 44, Issue 1, pp. 46 - 50
Journal Article
Annals of Oncology, ISSN 0923-7534, 01/2019, Volume 30, Issue 1, pp. 6 - 8
Journal Article
Cancers, ISSN 2072-6694, 07/2019, Volume 11, Issue 7, p. 952
BACKGROUNDThis study investigated the impact of baseline liver function according to the Child-Pugh score and ALBI (albumin-bilirubin) grade on the outcomes of... 
Child–Pugh score | lenvatinib | hepatocellular carcinoma | ALBI grade
Journal Article
by Zhang, Q and LiU, HY and Wang, HH and Lu, MM and Miao, YN and Ding, JG and Li, HZ and Gao, XG and Sun, SS and Zheng, JN
AMERICAN JOURNAL OF CANCER RESEARCH, ISSN 2156-6976, 2019, Volume 9, Issue 7, pp. 1382 - 1395
Based on previous reports, the efficacy of lenvatinib against cancer is mainly attributed to its antiangiogenic activity and its ability to suppress tumor... 
chemokine | ANGIOGENESIS | EFFICACY | melanoma | renal cancer | COMBINATION | CANCER | INHIBITOR LENVATINIB | E7080 | ONCOLOGY | NK cell | GROWTH | RESISTANCE | tumor infiltration | Lenvatinib | activation
Journal Article
International Journal of Oral and Maxillofacial Surgery, ISSN 0901-5027, 08/2019
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 12/2018, Volume 105, pp. S242 - S254
Metastatic Renal Cell Carcinoma: how to choose the appropriate second-line treatment?: The treatment of advanced or metastatic renal cell cancer (RCC) has... 
Cabozantinib | Nivolumab | Renal cell cancer | Axitinib | Lenvatinib | Second-line | Everolimus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2018, Volume 24, Issue 20, pp. 4968 - 4975
Purpose: Despite development of clinical "value frameworks" by national and international groups, there remains no generally accepted method to summarize... 
LENVATINIB | MAGNITUDE | BENEFIT | ONCOLOGY | ONCOLOGY VALUE FRAMEWORK | VERSION | COMMON TERMINOLOGY CRITERIA | BURDEN | AMERICAN SOCIETY | ADVERSE EVENTS | PATIENT-REPORTED OUTCOMES
Journal Article
by Yao, X and Wang, L and Gao, JJ
BioScience Trends, ISSN 1881-7815, 06/2019, Volume 13, Issue 3, pp. 282 - 283
Hepatocellular carcinoma (HCC) is a prevalent and refractory cancer in the world and very few drugs are available for the disease treatment currently.... 
HCC | immune checkpoint inhibitor | sorafenib | lenvatinib | PD-1 | BIOLOGY
Journal Article
BULLETIN DU CANCER, ISSN 0007-4551, 11/2016, Volume 103, Issue 11, pp. 905 - 910
Differentiated thyroid cancers are usually cured by an appropriate surgery and a radioiodine remnant ablation. If metastases occur, successive radioiodine... 
TRIAL | MULTIKINASE INHIBITOR LENVATINIB | PLACEBO | Thyroid cancer | ADVANCED SOLID TUMORS | ONCOLOGY | Sorafenib | Lenvatinib | CANCER | Radioiodine refractory
Journal Article
WORLD JOURNAL OF GASTROENTEROLOGY, ISSN 1007-9327, 05/2019, Volume 25, Issue 19, pp. 2365 - 2372
BACKGROUND Lenvatinib is one of the first-line tyrosine kinase inhibitors used for unresectable hepatocellular carcinoma (HCC). In the present study, we... 
CONTRAST-ENHANCED ULTRASONOGRAPHY | THERAPY | Contrast-enhanced ultrasound | Time-intensity curve | Hepatocellular carcinoma | Lenvatinib | SORAFENIB | GASTROENTEROLOGY & HEPATOLOGY | Prospective Study
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.